Drugs / CABTREO
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CABTREO | — | 2023-10-20 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07524946 | Apr 2026 → Dec 2027 expected | acne | Bausch Health Americas, Inc. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CABTREO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07524946 ↗ |
| Route | Topical | “The study drug will be applied topically to the treatment areas at home” NCT07524946 ↗ |